Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

Reckitt Benckiser has agreed to pay up to $1.4 billion to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment. Reuters Health News

https://en.ojaghia.vet

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.